Compile Data Set for Download or QSAR
Report error Found 137 Enz. Inhib. hit(s) with all data for entry = 10418
TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Gilead Sciences

WIPO
LigandPNGBDBM534230(WO2022081973, Example 34 | ((2R,3S,4R,5R)-5-(4-ami...)
Affinity DataEC50:  11nMAssay Description:Antiviral activity of compounds against SARS-CoV-2 is evaluated as described in Xue, Xi et al.2020. Briefly, the human alveolar epithelial cell line ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/24/2022
Entry Details
WIPO WO2022081973

TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Gilead Sciences

WIPO
LigandPNGBDBM534252(WO2022081973, Example 56 | ((2R,3S,4R,5R)-5-(4-ami...)
Affinity DataEC50:  13nMAssay Description:Antiviral activity of compounds against SARS-CoV-2 is evaluated as described in Xue, Xi et al.2020. Briefly, the human alveolar epithelial cell line ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/24/2022
Entry Details
WIPO WO2022081973

TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Gilead Sciences

WIPO
LigandPNGBDBM534244(WO2022081973, Example 48 | ((2R,3S,4R,5R)-5-(4-ami...)
Affinity DataEC50:  17nMAssay Description:Antiviral activity of compounds against SARS-CoV-2 is evaluated as described in Xue, Xi et al.2020. Briefly, the human alveolar epithelial cell line ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/24/2022
Entry Details
WIPO WO2022081973

TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Gilead Sciences

WIPO
LigandPNGBDBM534248(WO2022081973, Example 52)
Affinity DataEC50:  17nMAssay Description:Antiviral activity of compounds against SARS-CoV-2 is evaluated as described in Xue, Xi et al.2020. Briefly, the human alveolar epithelial cell line ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/24/2022
Entry Details
WIPO WO2022081973

TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Gilead Sciences

WIPO
LigandPNGBDBM534272(WO2022081973, Example 75 | ((2R,3S,4R,5R)-5-(4-ami...)
Affinity DataEC50:  17nMAssay Description:Antiviral activity of compounds against SARS-CoV-2 is evaluated as described in Xue, Xi et al.2020. Briefly, the human alveolar epithelial cell line ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/24/2022
Entry Details
WIPO WO2022081973

TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Gilead Sciences

WIPO
LigandPNGBDBM534245(WO2022081973, Example 49 | ((2R,3S,4R,5R)-5-(4-ami...)
Affinity DataEC50:  23nMAssay Description:Antiviral activity of compounds against SARS-CoV-2 is evaluated as described in Xue, Xi et al.2020. Briefly, the human alveolar epithelial cell line ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/24/2022
Entry Details
WIPO WO2022081973

TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Gilead Sciences

WIPO
LigandPNGBDBM534246(WO2022081973, Example 54 | ((2R,3S,4R,5R)-5-(4-ami...)
Affinity DataEC50:  24nMAssay Description:Antiviral activity of compounds against SARS-CoV-2 is evaluated as described in Xue, Xi et al.2020. Briefly, the human alveolar epithelial cell line ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/24/2022
Entry Details
WIPO WO2022081973

TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Gilead Sciences

WIPO
LigandPNGBDBM534251(WO2022081973, Example 55 | ((2R,3S,4R,5R)-5-(4-ami...)
Affinity DataEC50:  24nMAssay Description:Antiviral activity of compounds against SARS-CoV-2 is evaluated as described in Xue, Xi et al.2020. Briefly, the human alveolar epithelial cell line ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/24/2022
Entry Details
WIPO WO2022081973

TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Gilead Sciences

WIPO
LigandPNGBDBM534271(WO2022081973, Example 74 | ((2R,3S,4R,5R)-5-(4-ami...)
Affinity DataEC50:  24nMAssay Description:Antiviral activity of compounds against SARS-CoV-2 is evaluated as described in Xue, Xi et al.2020. Briefly, the human alveolar epithelial cell line ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/24/2022
Entry Details
WIPO WO2022081973

TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Gilead Sciences

WIPO
LigandPNGBDBM534249(WO2022081973, Example 53 | ((2R,3S,4R,5R)-5-(4-ami...)
Affinity DataEC50:  25nMAssay Description:Antiviral activity of compounds against SARS-CoV-2 is evaluated as described in Xue, Xi et al.2020. Briefly, the human alveolar epithelial cell line ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/24/2022
Entry Details
WIPO WO2022081973

TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Gilead Sciences

WIPO
LigandPNGBDBM534242(WO2022081973, Example 46 | ((2R,3S,4R,5R)-5-(4-ami...)
Affinity DataEC50:  26nMAssay Description:Antiviral activity of compounds against SARS-CoV-2 is evaluated as described in Xue, Xi et al.2020. Briefly, the human alveolar epithelial cell line ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/24/2022
Entry Details
WIPO WO2022081973

TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Gilead Sciences

WIPO
LigandPNGBDBM534243(WO2022081973, Example 47 | ((2R,3S,4R,5R)-5-(4-ami...)
Affinity DataEC50:  32nMAssay Description:Antiviral activity of compounds against SARS-CoV-2 is evaluated as described in Xue, Xi et al.2020. Briefly, the human alveolar epithelial cell line ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/24/2022
Entry Details
WIPO WO2022081973

TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Gilead Sciences

WIPO
LigandPNGBDBM534228(WO2022081973, Example 32 | ((2R,3S,4R,5R)-5-(4-ami...)
Affinity DataEC50:  40nMAssay Description:Antiviral activity of compounds against SARS-CoV-2 is evaluated as described in Xue, Xi et al.2020. Briefly, the human alveolar epithelial cell line ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/24/2022
Entry Details
WIPO WO2022081973

TargetReplicase polyprotein 1ab(2019-nCoV)
Gilead Sciences

WIPO
LigandPNGBDBM534230(WO2022081973, Example 34 | ((2R,3S,4R,5R)-5-(4-ami...)
Affinity DataEC50:  43nMAssay Description:Antiviral activity of compounds against SARS-CoV-2 is evaluated as described in Xue, Xi et al.2020. Briefly, the human alveolar epithelial cell line ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/24/2022
Entry Details
WIPO WO2022081973

TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Gilead Sciences

WIPO
LigandPNGBDBM534207(WO2022081973, Example 11 | ((2R,3S,4R,5R)-5-(4-ami...)
Affinity DataEC50:  47nMAssay Description:Antiviral activity of compounds against SARS-CoV-2 is evaluated as described in Xue, Xi et al.2020. Briefly, the human alveolar epithelial cell line ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/24/2022
Entry Details
WIPO WO2022081973

TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Gilead Sciences

WIPO
LigandPNGBDBM534201(WO2022081973, Example 67 | ((2R,3S,4R,5R)-5-(4-ami...)
Affinity DataEC50:  50nMAssay Description:Antiviral activity of compounds against SARS-CoV-2 is evaluated as described in Xue, Xi et al.2020. Briefly, the human alveolar epithelial cell line ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/24/2022
Entry Details
WIPO WO2022081973

TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Gilead Sciences

WIPO
LigandPNGBDBM534210(WO2022081973, Example 14 | 2-(((2R)-1-(((((2R,3S,4...)
Affinity DataEC50:  53nMAssay Description:Antiviral activity of compounds against SARS-CoV-2 is evaluated as described in Xue, Xi et al.2020. Briefly, the human alveolar epithelial cell line ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/24/2022
Entry Details
WIPO WO2022081973

TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Gilead Sciences

WIPO
LigandPNGBDBM534206(WO2022081973, Example 10 | ((2R,3S,4R,5R)-5-(4-ami...)
Affinity DataEC50:  55nMAssay Description:Antiviral activity of compounds against SARS-CoV-2 is evaluated as described in Xue, Xi et al.2020. Briefly, the human alveolar epithelial cell line ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/24/2022
Entry Details
WIPO WO2022081973

TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Gilead Sciences

WIPO
LigandPNGBDBM534270(WO2022081973, Example 73 | ((2R,3S,4R,5R)-5-(4-ami...)
Affinity DataEC50:  58nMAssay Description:Antiviral activity of compounds against SARS-CoV-2 is evaluated as described in Xue, Xi et al.2020. Briefly, the human alveolar epithelial cell line ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/24/2022
Entry Details
WIPO WO2022081973

TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Gilead Sciences

WIPO
LigandPNGBDBM534239(WO2022081973, Example 43 | ((2R,3S,4R,5R)-5-(4-ami...)
Affinity DataEC50:  59nMAssay Description:Antiviral activity of compounds against SARS-CoV-2 is evaluated as described in Xue, Xi et al.2020. Briefly, the human alveolar epithelial cell line ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/24/2022
Entry Details
WIPO WO2022081973

TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Gilead Sciences

WIPO
LigandPNGBDBM534237(WO2022081973, Example 41 | ((2R,3S,4R,5R)-5-(4-ami...)
Affinity DataEC50:  63nMAssay Description:Antiviral activity of compounds against SARS-CoV-2 is evaluated as described in Xue, Xi et al.2020. Briefly, the human alveolar epithelial cell line ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/24/2022
Entry Details
WIPO WO2022081973

TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Gilead Sciences

WIPO
LigandPNGBDBM534246(WO2022081973, Example 54 | ((2R,3S,4R,5R)-5-(4-ami...)
Affinity DataEC50:  64nMAssay Description:Antiviral activity of compounds against SARS-CoV-2 is evaluated as described in Xue, Xi et al.2020. Briefly, the human alveolar epithelial cell line ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/24/2022
Entry Details
WIPO WO2022081973

TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Gilead Sciences

WIPO
LigandPNGBDBM534268(WO2022081973, Example 71 | ((2R,3S,4R,5R)-5-(4-ami...)
Affinity DataEC50:  68nMAssay Description:Antiviral activity of compounds against SARS-CoV-2 is evaluated as described in Xue, Xi et al.2020. Briefly, the human alveolar epithelial cell line ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/24/2022
Entry Details
WIPO WO2022081973

TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Gilead Sciences

WIPO
LigandPNGBDBM534214(WO2022081973, Example 18 | ((2R,3S,4R,5R)-5-(4-ami...)
Affinity DataEC50:  69nMAssay Description:Antiviral activity of compounds against SARS-CoV-2 is evaluated as described in Xue, Xi et al.2020. Briefly, the human alveolar epithelial cell line ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/24/2022
Entry Details
WIPO WO2022081973

TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Gilead Sciences

WIPO
LigandPNGBDBM534225(WO2022081973, Example 29 | ((2R,3S,4R,5R)-5-(4-ami...)
Affinity DataEC50:  70nMAssay Description:Antiviral activity of compounds against SARS-CoV-2 is evaluated as described in Xue, Xi et al.2020. Briefly, the human alveolar epithelial cell line ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/24/2022
Entry Details
WIPO WO2022081973

TargetReplicase polyprotein 1ab(2019-nCoV)
Gilead Sciences

WIPO
LigandPNGBDBM534272(WO2022081973, Example 75 | ((2R,3S,4R,5R)-5-(4-ami...)
Affinity DataEC50:  72nMAssay Description:Antiviral activity of compounds against SARS-CoV-2 is evaluated as described in Xue, Xi et al.2020. Briefly, the human alveolar epithelial cell line ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/24/2022
Entry Details
WIPO WO2022081973

TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Gilead Sciences

WIPO
LigandPNGBDBM534220(WO2022081973, Example 24 | ((2R,3S,4R,5R)-5-(4-Ami...)
Affinity DataEC50:  73nMAssay Description:Antiviral activity of compounds against SARS-CoV-2 is evaluated as described in Xue, Xi et al.2020. Briefly, the human alveolar epithelial cell line ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/24/2022
Entry Details
WIPO WO2022081973

TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Gilead Sciences

WIPO
LigandPNGBDBM534235(WO2022081973, Example 39 | ((2R,3S,4R,5R)-5-(4-ami...)
Affinity DataEC50:  78nMAssay Description:Antiviral activity of compounds against SARS-CoV-2 is evaluated as described in Xue, Xi et al.2020. Briefly, the human alveolar epithelial cell line ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/24/2022
Entry Details
WIPO WO2022081973

TargetReplicase polyprotein 1ab(2019-nCoV)
Gilead Sciences

WIPO
LigandPNGBDBM534239(WO2022081973, Example 43 | ((2R,3S,4R,5R)-5-(4-ami...)
Affinity DataEC50:  79nMAssay Description:Antiviral activity of compounds against SARS-CoV-2 is evaluated as described in Xue, Xi et al.2020. Briefly, the human alveolar epithelial cell line ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/24/2022
Entry Details
WIPO WO2022081973

TargetReplicase polyprotein 1ab(2019-nCoV)
Gilead Sciences

WIPO
LigandPNGBDBM534268(WO2022081973, Example 71 | ((2R,3S,4R,5R)-5-(4-ami...)
Affinity DataEC50:  79nMAssay Description:Antiviral activity of compounds against SARS-CoV-2 is evaluated as described in Xue, Xi et al.2020. Briefly, the human alveolar epithelial cell line ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/24/2022
Entry Details
WIPO WO2022081973

TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Gilead Sciences

WIPO
LigandPNGBDBM534241(WO2022081973, Example 45 | ((2R,3S,4R,5R)-5-(4-ami...)
Affinity DataEC50:  82nMAssay Description:Antiviral activity of compounds against SARS-CoV-2 is evaluated as described in Xue, Xi et al.2020. Briefly, the human alveolar epithelial cell line ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/24/2022
Entry Details
WIPO WO2022081973

TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Gilead Sciences

WIPO
LigandPNGBDBM534219(WO2022081973, Example 23 | ((2R,3S,4R,5R)-5-(4-ami...)
Affinity DataEC50:  83nMAssay Description:Antiviral activity of compounds against SARS-CoV-2 is evaluated as described in Xue, Xi et al.2020. Briefly, the human alveolar epithelial cell line ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/24/2022
Entry Details
WIPO WO2022081973

TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Gilead Sciences

WIPO
LigandPNGBDBM534260(WO2022081973, Example 64 | [(2R,3S,4R,5R)-5-(4-Ami...)
Affinity DataEC50:  86nMAssay Description:Antiviral activity of compounds against SARS-CoV-2 is evaluated as described in Xue, Xi et al.2020. Briefly, the human alveolar epithelial cell line ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/24/2022
Entry Details
WIPO WO2022081973

TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Gilead Sciences

WIPO
LigandPNGBDBM534231(WO2022081973, Example 35 | ((2R,3S,4R,5R)-5-(4-ami...)
Affinity DataEC50:  95nMAssay Description:Antiviral activity of compounds against SARS-CoV-2 is evaluated as described in Xue, Xi et al.2020. Briefly, the human alveolar epithelial cell line ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/24/2022
Entry Details
WIPO WO2022081973

TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Gilead Sciences

WIPO
LigandPNGBDBM534212(WO2022081973, Example 16 | ((2R,3S,4R,5R)-5-(4-ami...)
Affinity DataEC50:  100nMAssay Description:Antiviral activity of compounds against SARS-CoV-2 is evaluated as described in Xue, Xi et al.2020. Briefly, the human alveolar epithelial cell line ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/24/2022
Entry Details
WIPO WO2022081973

TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Gilead Sciences

WIPO
LigandPNGBDBM534247(WO2022081973, Example 51 | ((2R,3S,4R,5R)-5-(4-ami...)
Affinity DataEC50:  100nMAssay Description:Antiviral activity of compounds against SARS-CoV-2 is evaluated as described in Xue, Xi et al.2020. Briefly, the human alveolar epithelial cell line ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/24/2022
Entry Details
WIPO WO2022081973

TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Gilead Sciences

WIPO
LigandPNGBDBM534267(WO2022081973, Example 70 | ((2R,3S,4R,5R)-5-(4-ami...)
Affinity DataEC50:  100nMAssay Description:Antiviral activity of compounds against SARS-CoV-2 is evaluated as described in Xue, Xi et al.2020. Briefly, the human alveolar epithelial cell line ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/24/2022
Entry Details
WIPO WO2022081973

TargetReplicase polyprotein 1ab(2019-nCoV)
Gilead Sciences

WIPO
LigandPNGBDBM534201(WO2022081973, Example 67 | ((2R,3S,4R,5R)-5-(4-ami...)
Affinity DataEC50:  120nMAssay Description:Antiviral activity of compounds against SARS-CoV-2 is evaluated as described in Xue, Xi et al.2020. Briefly, the human alveolar epithelial cell line ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/24/2022
Entry Details
WIPO WO2022081973

TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Gilead Sciences

WIPO
LigandPNGBDBM534229(WO2022081973, Example 33 | ((2R,3S,4R,5R)-5-(4-ami...)
Affinity DataEC50:  120nMAssay Description:Antiviral activity of compounds against SARS-CoV-2 is evaluated as described in Xue, Xi et al.2020. Briefly, the human alveolar epithelial cell line ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/24/2022
Entry Details
WIPO WO2022081973

TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Gilead Sciences

WIPO
LigandPNGBDBM534213(WO2022081973, Example 17 | (2R)-1-(((((2R,3S,4R,5R...)
Affinity DataEC50:  120nMAssay Description:Antiviral activity of compounds against SARS-CoV-2 is evaluated as described in Xue, Xi et al.2020. Briefly, the human alveolar epithelial cell line ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/24/2022
Entry Details
WIPO WO2022081973

TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Gilead Sciences

WIPO
LigandPNGBDBM534265(WO2022081973, Example 68 | O-(((2R,3S,4R,5R)-5-(4-...)
Affinity DataEC50:  120nMAssay Description:Antiviral activity of compounds against SARS-CoV-2 is evaluated as described in Xue, Xi et al.2020. Briefly, the human alveolar epithelial cell line ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/24/2022
Entry Details
WIPO WO2022081973

TargetReplicase polyprotein 1ab(2019-nCoV)
Gilead Sciences

WIPO
LigandPNGBDBM534243(WO2022081973, Example 47 | ((2R,3S,4R,5R)-5-(4-ami...)
Affinity DataEC50:  120nMAssay Description:Antiviral activity of compounds against SARS-CoV-2 is evaluated as described in Xue, Xi et al.2020. Briefly, the human alveolar epithelial cell line ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/24/2022
Entry Details
WIPO WO2022081973

TargetReplicase polyprotein 1ab(2019-nCoV)
Gilead Sciences

WIPO
LigandPNGBDBM534242(WO2022081973, Example 46 | ((2R,3S,4R,5R)-5-(4-ami...)
Affinity DataEC50:  120nMAssay Description:Antiviral activity of compounds against SARS-CoV-2 is evaluated as described in Xue, Xi et al.2020. Briefly, the human alveolar epithelial cell line ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/24/2022
Entry Details
WIPO WO2022081973

TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Gilead Sciences

WIPO
LigandPNGBDBM534240(WO2022081973, Example 44 | 3-((((2R)-1-(((((2R,3S,...)
Affinity DataEC50:  120nMAssay Description:Antiviral activity of compounds against SARS-CoV-2 is evaluated as described in Xue, Xi et al.2020. Briefly, the human alveolar epithelial cell line ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/24/2022
Entry Details
WIPO WO2022081973

TargetReplicase polyprotein 1ab(2019-nCoV)
Gilead Sciences

WIPO
LigandPNGBDBM534228(WO2022081973, Example 32 | ((2R,3S,4R,5R)-5-(4-ami...)
Affinity DataEC50:  120nMAssay Description:Antiviral activity of compounds against SARS-CoV-2 is evaluated as described in Xue, Xi et al.2020. Briefly, the human alveolar epithelial cell line ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/24/2022
Entry Details
WIPO WO2022081973

TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Gilead Sciences

WIPO
LigandPNGBDBM534226(WO2022081973, Example 30 | ((2R,3S,4R,5R)-5-(4-ami...)
Affinity DataEC50:  130nMAssay Description:Antiviral activity of compounds against SARS-CoV-2 is evaluated as described in Xue, Xi et al.2020. Briefly, the human alveolar epithelial cell line ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/24/2022
Entry Details
WIPO WO2022081973

TargetReplicase polyprotein 1ab(2019-nCoV)
Gilead Sciences

WIPO
LigandPNGBDBM534237(WO2022081973, Example 41 | ((2R,3S,4R,5R)-5-(4-ami...)
Affinity DataEC50:  130nMAssay Description:Antiviral activity of compounds against SARS-CoV-2 is evaluated as described in Xue, Xi et al.2020. Briefly, the human alveolar epithelial cell line ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/24/2022
Entry Details
WIPO WO2022081973

TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Gilead Sciences

WIPO
LigandPNGBDBM534211(WO2022081973, Example 15 | ((2R,3S,4R,5R)-5-(4-ami...)
Affinity DataEC50:  140nMAssay Description:Antiviral activity of compounds against SARS-CoV-2 is evaluated as described in Xue, Xi et al.2020. Briefly, the human alveolar epithelial cell line ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/24/2022
Entry Details
WIPO WO2022081973

TargetReplicase polyprotein 1ab(2019-nCoV)
Gilead Sciences

WIPO
LigandPNGBDBM534241(WO2022081973, Example 45 | ((2R,3S,4R,5R)-5-(4-ami...)
Affinity DataEC50:  140nMAssay Description:Antiviral activity of compounds against SARS-CoV-2 is evaluated as described in Xue, Xi et al.2020. Briefly, the human alveolar epithelial cell line ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/24/2022
Entry Details
WIPO WO2022081973

TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Gilead Sciences

WIPO
LigandPNGBDBM534218(WO2022081973, Example 22 | ((2R,3S,4R,5R)-5-(4-ami...)
Affinity DataEC50:  150nMAssay Description:Antiviral activity of compounds against SARS-CoV-2 is evaluated as described in Xue, Xi et al.2020. Briefly, the human alveolar epithelial cell line ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/24/2022
Entry Details
WIPO WO2022081973

Displayed 1 to 50 (of 137 total ) | Next | Last >>
Jump to: